Peptide · Fact sheet
Plecanatide
Also known as Trulance · uroguanylin analog
Plecanatide is FDA approved as Trulance for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It is not approved for general gut health, detoxification, inflammation, or tissue repair.
What is Plecanatide?
Plecanatide is a 16-amino-acid analog of uroguanylin that activates guanylate cyclase-C on the intestinal surface.
Like linaclotide, it is minimally absorbed and its evidence is tied to local bowel and abdominal-symptom outcomes.
Benefits & claims
It offers a second approved peptide approach to gut-surface guanylate cyclase-C signaling.
Comparing it with linaclotide illustrates why related mechanisms still require product-specific efficacy and safety evidence.
What the evidence supports
- Controlled trials found higher composite response rates than placebo for IBS-C and chronic idiopathic constipation.
- Benefits are averages in defined trial populations and do not imply response for every person with constipation.
Research areas
- Chronic idiopathic constipation
- IBS with constipation
- Abdominal pain and bloating
- Bowel-frequency outcomes
- Additional analyses of symptom response within the approved adult populations
Dosage & frequency
Product-specific label informationTrulance has a once-daily adult regimen for chronic idiopathic constipation and IBS-C.
Trulance
Adults with chronic idiopathic constipation or IBS-C
- Amount
- 3 mg
- Frequency
- Once daily
- Route studied or labeled
- Oral
With or without food; pediatric restrictions and obstruction contraindication apply.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- The oral tablet acts through guanylate cyclase-C in the intestinal lumen.
Interactions & precautions
- The label describes low interaction potential in vitro; these findings do not establish clinical safety for every combination.
What is still unresolved
- The adult regimen is not established for pediatric treatment; the label has pediatric restrictions.
Side effects & risks
- The label carries a boxed warning about serious dehydration in young pediatric patients and is not approved for pediatric use.
- Diarrhea is the most common adverse reaction and can be severe.
- It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesMultiple Phase 3 trials support the adult constipation indications. Evidence does not extend to children, unrelated digestive conditions, or broad gut-wellness claims.
Studies
Controlled adult evidence for composite and individual symptom outcomes.
Subgroup analysis illustrating efficacy, safety, and limitations in older participants.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Pain: reported experiences
Less constipation and cramping
A separate commenter described relief from constipation and painful cramping while also using a probiotic and pantoprazole.
Reported use in this account
- Product
- Trulance
- Amount
- Not specified clearly
- Frequency
- At night; exact frequency not stated
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: A live probiotic; Pantoprazole
Concurrent treatments, diagnosis and symptom changes were not independently checked.
Read the original accountDelayed bowel movements after colon surgery
A person with prior sigmoid-colon surgery described bowel movements eventually occurring after Trulance, with considerable pain during the wait and relief afterwards. They were also using other laxatives.
Reported use in this account
- Product
- Trulance
- Amount
- 3 mg
- Frequency
- Not specified clearly
- Route
- Oral, taken with water
- Duration
- Three weeks at the report
Other exposures described: Polyethylene glycol; Other laxatives used during follow-up; Prior sigmoid-colon resection
Altered bowel anatomy and concurrent laxatives limit attribution. Later urgent-care discussion offered a different explanation for the pain; the author's electrolyte theory was not confirmed.
Read the original accountDigestion: reported experiences
Bowel relief alongside gas and diarrhea
An author described normal bowel movements after starting Trulance, but also bloating, gas and repeated diarrhea.
Reported use in this account
- Product
- Trulance
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- First day after starting
Other exposures described: Recent cannabis cessation; Earlier linaclotide, senna, polyethylene glycol and fiber products
The first-day account follows years of digestive symptoms, other treatments and a recent cannabis change. It does not establish longer-term response.
Read the original accountLess constipation and cramping
A separate commenter described relief from constipation and painful cramping while also using a probiotic and pantoprazole.
Reported use in this account
- Product
- Trulance
- Amount
- Not specified clearly
- Frequency
- At night; exact frequency not stated
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: A live probiotic; Pantoprazole
Concurrent treatments, diagnosis and symptom changes were not independently checked.
Read the original accountMostly no response, with one diarrhea episode
Another commenter reported little benefit overall, but an abrupt episode of diarrhea five days after starting that disrupted work.
Reported use in this account
- Product
- Trulance; the commenter's strength not stated
- Amount
- Not specified clearly
- Frequency
- After work; exact frequency not stated
- Route
- Not specified clearly
- Duration
- At least five days before the diarrhea episode; total exposure not stated
Other exposures described: Other morning medication, not identified
The account lacks a clinical assessment and other-treatment details. A single episode cannot estimate frequency or cause.
Read the original accountDelayed bowel movements after colon surgery
A person with prior sigmoid-colon surgery described bowel movements eventually occurring after Trulance, with considerable pain during the wait and relief afterwards. They were also using other laxatives.
Reported use in this account
- Product
- Trulance
- Amount
- 3 mg
- Frequency
- Not specified clearly
- Route
- Oral, taken with water
- Duration
- Three weeks at the report
Other exposures described: Polyethylene glycol; Other laxatives used during follow-up; Prior sigmoid-colon resection
Altered bowel anatomy and concurrent laxatives limit attribution. Later urgent-care discussion offered a different explanation for the pain; the author's electrolyte theory was not confirmed.
Read the original accountNo clear change: reported experiences
Mostly no response, with one diarrhea episode
Another commenter reported little benefit overall, but an abrupt episode of diarrhea five days after starting that disrupted work.
Reported use in this account
- Product
- Trulance; the commenter's strength not stated
- Amount
- Not specified clearly
- Frequency
- After work; exact frequency not stated
- Route
- Not specified clearly
- Duration
- At least five days before the diarrhea episode; total exposure not stated
Other exposures described: Other morning medication, not identified
The account lacks a clinical assessment and other-treatment details. A single episode cannot estimate frequency or cause.
Read the original accountApproval status
Trulance is FDA approved for adults with chronic idiopathic constipation and adults with irritable bowel syndrome with constipation.
Approved uses
- Chronic idiopathic constipation and IBS with constipation in adults under the Trulance label
FDA approved for adult constipation indications
Plecanatide is approved under the Trulance label for chronic idiopathic constipation and IBS with constipation in adults.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term head-to-head effectiveness versus linaclotide and other approved options
- Reliable predictors of response and severe diarrhea
- Safety and effectiveness outside the approved adult populations
- Whether exploratory symptom composites translate into meaningful daily-life improvement
Summary
Trulance is approved for two adult constipation disorders, not general gut health or tissue repair.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Trulance
Approved adult indications, boxed warning, contraindications, and adverse reactions.
- pubmedIntegrated analysis of two Phase 3 IBS-C trials
Controlled adult evidence for composite and individual symptom outcomes.
- pubmedPooled Phase 3 analysis in older adults
Subgroup analysis illustrating efficacy, safety, and limitations in older participants.